Lu Si

Snail1-Dependent Activation of Cancer-Associated Fibroblast Controls Epithelial Tumor Cell Invasion and Metastasis

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

Epidemiology and survival outcomes of ocular and mucosal melanomas: A population‐based analysis

De novo design of allosterically switchable protein assemblies

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy

New drugs in melanoma: It’s a whole new world

Targeting cancer stem cell pathways for cancer therapy

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells

Biological and molecular modifications induced by cadmium and arsenic during breast and prostate cancer development

Macrophages in immunoregulation and therapeutics

Genetically engineered T cells for cancer immunotherapy

Matrikines from basement membrane collagens: A new anti-cancer strategy

The JAK/STAT signaling pathway: from bench to clinic

Remodelling the extracellular matrix in development and disease

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Advances in systemic treatment of melanoma

Sub-nm resolution cavity enhanced microspectrometer

Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

The MAPK pathway across different malignancies: A new perspective

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)

Bladder Cancer

Nanotechnology for Multimodal Synergistic Cancer Therapy

The Effects of Cadmium Toxicity

Antibody-Drug Conjugates in Urothelial Carcinomas

Compact spectrometer based on a disordered photonic chip

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

The Repressive Effect of miR-148a on TGF beta-SMADs Signal Pathway Is Involved in the Glabridin-Induced Inhibition of the Cancer Stem Cells-Like Properties in Hepatocellular Carcinoma Cells

A phase II study of imatinib for advanced melanoma patients with KIT aberrations.

Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma

Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance

Design of flat-field arrayed waveguide grating with three stigmatic points

A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.

Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells